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Abstract
Purpose—To evaluate the psychometric properties of the original Parent and new Child
Amblyopia Treatment Index (ATI), questionnaires that assess the burden of amblyopia treatment
in children and families, and to compare scores between children treated with atropine or patching.
Methods—Parent ATI and Child ATI were administered to 233 children 7 to <13 years old and
their parents as part of a randomized trial comparing patching and atropine for amblyopia
treatment. For each ATI version, construct validity was assessed using factor analysis; internal
consistency reliability was assessed using Cronbach’s alpha. Data from the Parent ATI and Child
ATI were correlated and scores for each version were compared between treatment groups.
Results—We analyzed the three subscales found in prior Parent ATI studies in younger children
and confirmed subscales for adverse effects and treatment compliance, but not for social stigma, in
both parent and child versions. Overall and subscale scores on the Parent ATI and Child ATI were
moderately to well correlated except for the social stigma subscale. For both the Parent ATI and
Child ATI, children treated with atropine had better scores than those treated with patching, both
overall and on treatment compliance and social stigma subscales (all p-values ≤ 0.01).
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Conclusions—When used for children 7 to <13 years old, the Parent ATI and Child ATI have
similar factor structures to each other and to the Parent ATI for children 3 to <7 years old.
Atropine treatment was found to have less negative impact than patching.
Introduction
The Amblyopia Treatment Index (ATI) was developed by the Pediatric Eye Disease
Investigator Group to measure the impact or burden of amblyopia treatment on the child and
the family.1 Briefly, a list of potential questionnaire items had been created based on the
literature and clinical experience and was reviewed by pediatric eye specialists, a pediatric
psychologist, and parents of children aged 3 to <7 years old who were undergoing
amblyopia treatment.1 The list was then reduced to the 20 items that were felt to best address
various aspects of the psychological impact of amblyopia treatment.1 In children age 3 to <7
years, the original ATI demonstrated a three-factor structure, leading to the definition of
three subscales referred to as “adverse effects,” “treatment compliance,” and “social
stigma,” each with good internal consistency and reliability.1-3 Parallel versions of the ATI
were developed for patching treatment and for atropine treatment.1
Previous studies using the original ATI, all of which have been in patients 3 to <7 years old,
have involved questionnaire completion by the parent,1-7 which is typical when evaluating
treatment in young children. For children aged 7 years and older, we developed a child
version of the ATI (the Child ATI) to allow assessment of the impact of treatment from the
child’s perspective.
In the present study we administered both the new Child ATI and the original ATI
(henceforth referred to as the Parent ATI) as part of a randomized clinical trial comparing
amblyopia treatments in children aged 7 to <13 years.8 Herein we evaluate the ATI results
from that trial to determine whether the Parent ATI shows a similar factor structure in older
children, to assess the psychometric properties of the Child ATI, to correlate Parent ATI and
Child ATI results, and to compare ATI results between the treatment groups.
Methods
This study was conducted by the Pediatric Eye Disease Investigator Group (PEDIG). The
respective institutional review boards approved the protocol and the Health Insurance
Portability and Accountability Act–compliant informed consent forms. The parent or
guardian of each participant gave written informed consent and each participant gave assent
as required.
The ATI was completed as part of a randomized trial comparing atropine to patching for
treatment of amblyopia in children aged 7 to <13 years. The details of the protocol have
been published in a previous report,8 but are briefly summarized herein. Patients with
moderate or severe amblyopia (amblyopic eye visual acuity 20/40 to 20/400) were
randomized to either 2 hours of daily patching or atropine 1% once each weekend day in the
sound eye and had follow-up visits 5 weeks and 17 weeks after randomization. Each child
and accompanying parent completed the ATI at each follow-up visit, prior to the child’s
examination. If the child was not accompanied by a parent who was responsible for
administering the treatment at least half of the time, the parent questionnaire was not
completed. The parent version of the questionnaire was self-administered whereas the child
version of the questionnaire was verbally administered by clinic staff.
The Parent ATI consists of 20 items and the Child ATI consists of 19 items reworded to
address the impact of treatment from the child’s perspective. Items in the atropine treatment
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versions of the Parent ATI and Child ATI are shown in Table 1; items in the patching
treatment versions are shown in e-Supplement 2 (available at jaapos.org). Both
questionnaires are scored on a 5-point Likert scale, but the parent questionnaire uses a
strength of agreement scale with responses of “strongly agree” (5), “agree” (4), “neither
agree nor disagree” (3), “disagree” (2), “strongly disagree” (1), and “not applicable,”
whereas the child questionnaire uses a frequency scale with responses of “always” (5), “a
lot” (4), “sometimes” (3), “a little” (2), “never” (1), and “not applicable.” On both
questionnaires the majority of items are negative statements; therefore a higher score
indicates higher negative impact or higher burden. Reverse scoring was applied to the few
items that are positive statements.
Three subscales were predefined based on the past reports of the Parent ATI in younger
children and the corollary questions on the Child ATI (Table 1a).
Statistical Analysis
Questionnaires with 3 or more missing or not-applicable responses were excluded from the
analyses. For the remaining questionnaires, the missing or not-applicable responses were
imputed using the average score for all completed items.
We examined the psychometric properties of the Parent ATI and Child ATI separately,
using data pooled across treatment groups from the 5-week visit only because the 17-week
data might have been affected by knowledge of whether visual acuity had improved at the 5-
week visit. We assessed construct validity by performing factor analysis,9,10 a statistical
procedure that attempts to describe a battery of questionnaire items in terms of a smaller
number of underlying factors. An orthogonal varimax rotation11 was used for the factor
analysis to simplify the interpretation of the results by determining factors whereby each
individual item is strongly correlated with only one factor (or a small number of factors) and
each factor is strongly correlated with only a few items.12
Item loadings, an estimate of the correlation between the item and an underlying factor,
were considered to have “loaded” on a particular factor if they were at least 0.50.
Eigenvalues, representing the amount of combined item variance accounted for by each
factor, were examined. Factor analysis was first performed using a three-factor solution in
accordance with previous studies of the Parent ATI, which had yielded three subscales.1-3
Additional factor analysis was performed using a solution based on the number of factors for
which eigenvalues exceeded 1.00. Internal consistency reliability of the overall score and of
previously defined subscale1-3 scores was assessed using Cronbach’s alpha.13
The correlation between the Parent ATI and the Child ATI at 5 weeks was assessed using
Spearman rank correlations on data pooled across treatment groups. Spearman rank
correlations were calculated between overall scores, between subscale scores, and between
each Parent ATI item and its parallel Child ATI item. Based on published guidelines (as
cited in Upton and colleagues14) correlations >0.50 were considered good, between 0.30 and
0.50 were considered moderate, and <0.30 were considered poor.
Overall scores and subscale scores were compared between treatment groups using the
Wilcoxon rank sum test with computation of exact p-values. The subscales were defined
according to the three a priori subscales based on previous factor analyses of the Parent ATI
in younger children.1-7 For this analysis, data from the 5-week visit and the 17-week visit
were analyzed separately. Results were evaluated both overall and stratified according to
amblyopia severity at baseline.
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Analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC) and StatXact
version 6.0 (Cytel, Cambridge, MA).
Results
ATI Completion and Demographics
At the 5-week visit, of the 233 patients in the randomized trial, 188 (81%) had both parent
and child questionnaires completed; 29 (12%) had only the child questionnaire completed,
and 16 (7%) had neither completed. At the 17-week visit, 157 (67%) patients had both
parent and child questionnaires completed, 39 (17%) had only the child questionnaire
completed, and 37 (16%) had neither completed. Across both visits, for the Parent ATI and
Child ATI respectively, 246 (71%) and 280 (68%) questionnaires had no missing or not
applicable items, 49 (14%) and 92 (22%) had 1, 25 (7%) and 19 (5%) had 2, and 25 (7%)
and 22 (5%) had 3 or more. Overall, 1.7% of item responses were marked not applicable and
0.02% were missing. Responses of not applicable were more likely to occur in the patching
group than in the atropine group (mean number of items not applicable = 0.82, vs 0.31 for
the Parent ATI and 0.78 vs 0.41 in the Child ATI).
Excluding the 47 questionnaires which had 3 or more items either missing or not applicable,
there were 172 parent and 206 child questionnaires for analysis at 5 weeks and 148 parent
and 185 child questionnaires for analysis at 17 weeks.
Of the 220 patients (92%) who completed at least one questionnaire during the study, 109
(51%) were female and 179 (83%) were white. Their mean age was 9.0 ± 1.6 years, with
120 patients (56%) 7 to <9 years, 63 patients (29%) 9 to <11 years, and 34 patients (15%) 11
to <13 years. Amblyopic eye visual acuity was between 20/40 to 20/100 in 179 patients
(83%) and between 20/125 to 20/400 in 37 (17%). Sixty (27%) had been previously treated
for amblyopia, most with patching. Baseline demographic and clinical characteristics were
similar comparing the 220 patients who had at least one questionnaire completed and the 13
patients who had no questionnaires completed (data not shown).
Distribution of Responses
Frequency distributions of item responses were visually inspected and a limited response
range was found for items 6b, 6c and 15 on the parent ATI (for items 6b and 6c, 94% of
responses were either “strongly disagree” or “disagree”; for item 15, 92% of responses were
either “strongly agree” or “agree”); and for items 6 and 7 on the Child ATI (for both items
94% of responses were “never”).
Factor Analysis and Internal Consistency Reliability
Parent ATI 5-Week Data—For the factor analysis of the Parent ATI, using a three-factor
solution, 15 of the 20 items had factor loadings ≥0.50 (Table 2). For the Parent ATI, two of
three factors (factors 1 and 2 respectively) appeared similar to previously described
subscales,1-3 with common themes of adverse effects and treatment compliance
(eigenvalues of 11.6 and 2.8) but the social stigma subscale did not appear to be present.
Items 6b and 6c alone, items which had been excluded from previous analyses, loaded
(≥0.50) on a third factor (0.84 and 0.70, respectively; eigenvalue, 2.0) possibly representing
tension/conflict with others. Given that four factors had eigenvalues greater than 1.00 (e-
Supplement 3, available at jaapos.org), we repeated the factor analysis using a four-factor
solution (Table 2). The results were largely similar except that loading on “adverse effects”
in the three-factor analysis were now divided into two factors.
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Internal consistency reliability of the Parent ATI as measured by Cronbach’s alpha was 0.88
overall, and was 0.84, 0.84, 0.65, for the previously defined1-3 adverse effect, treatment
compliance, and social stigma subscales respectively, and was 0.81 for the new factor
comprised of items 6b and 6c.
Child ATI 5-Week Data—For the factor analysis of the child questionnaire data, using a
three factor solution, 10 of the 19 items had factor loadings ≥0.50 (Table 3). The first and
second factors appeared similar to the previously described1-3 adverse effects and treatment
compliance subscales on the Parent ATI. Similar to the Parent ATI, the previously
described1-3 social stigma subscale did not emerge. Given that only 3 factors had
eigenvalues greater than 1.00 (ie, 8.0, 1.7 and 1.3 for factors 1, 2, and 3, respectively) (e-
Supplement 4, available at jaapos.org), no additional factor analysis was performed.
Internal consistency reliability for the Child ATI as measured by Cronbach’s alpha was 0.84
overall, and was 0.79, 0.70, 0.54 for the previously defined1-3 adverse effect, treatment
compliance, and social stigma subscales, respectively, and was 0.60 for the new factor found
in the Parent ATI data (items 6 and 7 on the Child ATI corresponding to items 6b and 6c on
the Parent ATI).
Correlation between Parent ATI and Child ATI Data at 5 Weeks
Spearman rank correlations between the Parent ATI and the Child ATI are shown in Table
4. The overall score and subscale scores for adverse effects and treatment compliance were
moderately correlated between the Parent ATI and the Child ATI, whereas subscale scores
for social stigma was poorly correlated. All correlations between parent items and parallel
child items were either moderate or poor.
Treatment Group Comparison
Patients in the atropine group had better (ie, lower) median overall scores at 17 weeks than
patients in the patching group on the Parent ATI (2.10 vs 2.30, p = 0.005) and on the Child
ATI (1.63 vs 2.00, p < 0.001). At 17 weeks, the atropine group had better median scores on
the treatment compliance (2.00 vs 2.60, p < 0.001 for the Parent ATI; 1.75 vs 2.75, p <
0.001 for the Child ATI) and social stigma (2.00 vs 2.33, p < 0.001 for the Parent ATI; 1.11
vs 1.67, p = 0.001 for the Child ATI) subscales, but not on the adverse effects subscale (2.25
vs 2.31, p = 0.45 for the Parent ATI; 1.75 vs 2.00, p = 0.05 for the Child ATI). Treatment
group scores stratified by baseline amblyopia eye acuity level are in online e-Supplement 5
(available at jaapos.org). Findings were similar at 5 weeks (data not shown). Results were
largely similar when the analysis was restricted to cases with no missing data.
Discussion
Previously we had developed a parent version of the ATI and evaluated it in parents of
children 3 to <7 years of age. In the current study, we administered the parent version and a
new child version to patients ages 7 to <13 years old and their parents as part of a
randomized trial comparing patching and atropine for the treatment of amblyopia.
For the Parent ATI, the similarity of factor structure in the present study of children 7 to <13
years old and in previous studies of of children 3 to <7 years old, with consistency of
adverse effects and treatment compliance subscales, suggest a robustness of the instrument
across 3 to <13-year-olds. The absence of a social stigma subscale in the present study might
be because the treatment regimens in the present study were less intense than those used in
previous studies of younger children (2 hours vs 6 hours to full-time patching),2, 4-6 and
could be completed while at home, away from friends and peers. Interestingly, the current
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analysis suggests a potential new factor on the Parent ATI consisting of two items that relate
to tension and conflict with others (6b and 6c), items which had been included in our present
analysis but excluded from the earlier reports.2-7
Although the evidence for the existence of subscales in the new Child ATI was less strong
than in the Parent ATI, we did find evidence of adverse effects and treatment compliance
subscales previously described in the Parent ATI, suggesting that both instruments are
measuring similar constructs. The third factor emerging in the analysis of the Child ATI is
comprised of items that are part of the previously defined adverse effects subscale but seem
to specifically relate to functioning at near.
The correlation between Parent ATI and Child ATI scores overall and on adverse effects and
treatment compliance subscale was moderate to good, however many individual items
showed poor correlation. Several factors may have negatively impacted affected the
correlation. First, the two questionnaires are on different response scales. Responses on the
Parent ATI are on a strength of agreement scale (“strongly agree” to “strongly disagree”)
whereas the responses on the Child ATI are on a frequency scale (“always” to “never”)
because we felt that a frequency scale might be more easily understandable to chidren.
Second, the child and parent versions might not be considered strictly parallel on the item
level. For example, several items developed with the intent of targeting parental worries
correlated poorly with their corresponding child ATI items. Also, the two Parent ATI items
relating to tension or conflict in relationships with the spouse or the child’s teacher do not
have a corresponding item on the Child ATI. Third, some individual items had only a
limited range of responses on the parent and/or child versions. Lastly, parents and children
may simply have different perspectives on the impact and burden of treatment.
The comparison of ATI scores between atropine treatment and patching treatment in these 7
to <13-year-olds yielded largely similar results to those found previously in 3 to <7-year-
olds.2-7 Overall ATI scores, treatment compliance subscale scores, and social stigma
subscale scores were more favorable in the children treated with atropine. Contrary to results
from previous studies of 3 to <7-year-olds, adverse effects subscale scores did not differ by
treatment group.2, 4 Our failure to find such a difference may be due to the lower intensity
treatment regimens in the present study.2,4 Most median treatment group differences were
less than a half a point, with the largest treatment group difference being 1.00 point. From a
relative perspective, an ATI score of 1 would be no treatment burden (0%) and a score of 5
would be maximum treatment burden (100%), therefore a half point difference in score
would represent a 12.5% difference in treatment burden if response categories are
equidistant. Median scores were between 1.63 and 2.31 for both treatment groups, indicating
that treatment was generally well-tolerated. To put a score into a meaningful context, a
median score of 2.00 on the Child ATI, for example, indicates that half of the group
experienced treatment-related difficulties less than “a little” of the time.
There are some limitations to our study. First, we are assuming that the previously-
established content validity of the Parent ATI in younger children would generalize to its
use in older children and to the analogous Child ATI. Second, although our Likert-type
scales were assigned numerical values for analysis, they are are technically ordinal,
therefore we do not know whether the distance between successive categories is the same—
that is, whether “strongly agree” and “agree” are the same distance apart as “agree” and
“neither agree or disagree.” In averaging item scores to calculate overall and subscale
scores, we are making the assumption that the response categories are equidistant.
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By assessing the burden of treatment, the Parent ATI and the Child ATI provide useful
additional information for parents and clinicians to consider when making management
decisions, particularly when treatments are equally effective.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 3







Items composing previously hypothesized adverse
effects subscale a
2 I can’t do fun things .56 .19 .01
3 Treatment makes my school work harder .32 .10 .54
4 Treatment makes it hard to play outside .65 .23 .13
8 Treatment makes it hard to read and writeb .29 .06 .76
9 I worry that I will run into things .68 .15 .20
10 I can see well on treatment .02 .01 .49
14 Treatment makes me clumsy .52 .27 .18
17 Treatment makes difficult for me to play with small toys,etc .53 .11 .44
Items composing previously hypothesized treatment
compliance subscale a
1 Using treatment bothers me .34 .55 .34
5 It’s hard to use the treatment .10 .73 .15
11 I don’t like when it is time for treatment .17 .60 .27
13 I worry I’m not getting enough treatment .30 .32 −.01
Items composing previously hypothesized social stigma
subscale *
12 Treatment makes my eye or eyelids red .26 .24 .18
15 My friends stare at me on treatment .36 .19 .01
19 Treatment makes me feel different from other children .38 .29 .13
Items not included in previously hypothesized subscales a
6 Treatment makes my parents argue .20 .26 −.01
7 Treatment makes others in my family argue .22 .35 −.01
16 I think the patch will help me see better −.06 .10 .35
18 My parents forget to apply my treatment .14 .39 .02
Factor loadings shown in bold are those which are ≥0.50.
a
Previously hypothesized subscales based on previous factor analysis of the parent questionnaire data in studies of younger children aged 3 to <7
years.1,3
b
In previous studies of the Parent ATI in younger children1-7 this item has related to treatment making it difficult for child to draw, color, or write.
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Table 4






 Adverse effectsb .49
 Treatment compliancec .61
 Social stigmad .26
Individual items e
1 Child does not seem to mind treatment .46
2 Worry that child on treatment may miss out on fun activities .26
3 Treatment affects child’s learning .28
4 Treatment makes it hard for child to play outside .30
5 Trouble applying treatment to child .38
6b Treatment is source of tension/conflict with another familymember −.01/.02
f
7 Treatment makes it difficult for child to read or writeg .50
8 Worry that child on treatment will become injured .09
9 Child can see well on treatment .19
10 Child complains when it is time for treatment .49
11 Treatment makes child’s eye or eyelids red .36
12 Worry child not getting enough treatment .32
13 Child more clumsy on treatment .34
14 Other children stare at child .23
15 Believe treatment will improve child’s vision .27
16 Treatment makes difficult for child to play with small toys orhandheld videogames .27
17 Sometimes forget to apply child’s treatment .37
18 Worry that child feels different from other children .19
ATI, Amblyopia Treatment Index
a
Previously hypothesized subscales based on previous factor analysis of the parent questionnaire data in studies of younger children aged 3 to <7
years.1,3
b
Adverse effects subscale consists of items 2, 3, 4, 7, 8, 9, 13 and 16 on parent questionnaire, and items 2, 3, 4, 8, 9, 10, 14 and 17 on child
questionnaire.
c
Treatment compliance subscale consists of items 1, 5, 6a, 10 and 12 on parent questionnaire, and items 1, 5, 11, and 13 on child questionnaire.
d
Social stigma subscale consists of items 11, 14, and 18 on parent questionnaire, and items 12, 14, and 17 on child questionnaire.
e
Item numbers cited are those from the Parent ATI. Parent ATI items 6a and 6c have no parallel items on the child questionnaire.
f
First number is from correlation of parent item 6b with child item 6. Second number is from correlation of parent item 6b with child item 7.
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g
Item 7 in previous studies of the Parent ATI in younger children1-7 has related to treatment making it difficult for child to draw, color, or write.
1-3
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